Navigation Links
Meningitis Shots for Teens

A bacterial meningitis case at the University of Cincinnati has resulted in the Advisers to the U.S. Centers for Disease Control and Prevention recommending that all teens between the ages of 11 and 18 be routinely vaccinated against potentially deadly bacterial meningitis.

The guidelines are especially aimed at protecting new college students, who have a higher-than-average risk of bacterial meningitis, the CDC said. Adolescents and young adults are at increased risk because of their more social lifestyle.

Bacterial meningitis is a rare infection that can prove fatal. The infection can cause seizures, brain damage, memory loss and death in otherwise healthy people in less than 48 hours. It has about a 15 percent fatality rate if treated with antibiotics.

Characterized by fever, headache, and stiff neck, the relatively rare disease involves the inflammation of membranes covering the brain and spinal cord. It is a more serious infection than viral meningitis.

The disease is often misdiagnosed in its early stage because symptoms resemble those of the flu, including fever, headache, nausea, vomiting and stiff neck, said National Meningitis Association board member Tama Lee. Bruising and a rash resembling small pin marks help distinguish the disease, which, if left untreated, can lead to brain damage, hearing loss, organ failure, loss of limbs and - sometimes - death.

It is spread through the exchange of respiratory droplets, or by sharing drinks or utensils or by kissing or coughing and sneezing. It's easily spread to people who live in crowded places like camps or dormitories.

The recommendation would expand the use of Sanofi-Pasteur's Menactra, also known as meningococcal polysaccharide vaccine or MCV4, which is now routinely recommended for all 11- and 12-year olds.

The vaccine has been proven to protect against up to 83 percent of meningococcal cases among adolescent
'"/>




Page: 1 2

Related medicine news :

1. Meningitis C vaccine a cost-effective success
2. Cure for Bacterial Meningitis
3. Efficacy Of Meningitis C Vaccine
4. Meningitis is rocking the capital again
5. Uganda Tackles The Meningitis Outbreak
6. Fatal Case of Meningitis Detected In Massachusetts
7. Meningitis Back in Delhi and 21 Dead
8. New Delhi Hit By Meningitis Deaths
9. Cost-effective Meningitis Vaccine To Be Launched In Africa
10. Delhi Witnessed 34 Meningitis Deaths In Three Months
11. Meningitis vaccine in a controversy regarding efficacy
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Meningitis Shots for Teens

(Date:8/29/2008)...INGTON, Aug. 29 /PRNewswire-USNewswire/ -- The fol...nt, Campaign for Tobacco-Free Kids:, For the seco...s had to,withdraw sponsorship and promotion of a c...international criticism for engaging in cigarette,...hilip Morris International has been forced to with...
(Date:8/29/2008)... First Walkathon to Benefit Muscu...Iselin, NJ (PRWEB) August 29, 2008 -- Students, fa...rd-Brown Iselin] (SBI), in New Jersey, raised $11,...r walkathon, last week. Proceeds from the event a...org [Ryan,s Quest]. The all-volunteer event was a...
(Date:8/29/2008)...WOOD, Ill., Aug. 29 /PRNewswire-FirstCall/ -- Land...ard of Directors declared a regular,quarterly cash...r of fiscal,2008. The dividend will be paid on Oct...er 12, 2008., About Landauer, Landauer is the le...,occupational and environmental radiation exposure...
(Date:8/29/2008)...oston Scientific obligation reduced from $250 to $...rstCall/ -- Boston Scientific,Corporation (NYSE: ... of,Marshall, Texas found two patents of Medtronic... conduct during the prosecution of the patents,bef..., A jury had previously found that certain Boston...
Breaking Medicine News(10 mins):Health News:Philip Morris International Forced to Drop Another Concert Sponsorship; Philippines Health Department Applauded for Taking Action 2Health News:Sanford-Brown Institute - Iselin Raises $11,000 for Ryan's Quest 2Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3
...ksburg: Procter & Gamble and the Industrial Design...mpetitive grant of $40,000 to a Virginia Tech team...ollege of Architecture and Urban Affairs for the d... that can add more value to the lives of elderly p...
...uala Lumpur, Malaysia a two-year-old boy dies at t...symptoms of the hand, foot and mouth disease (HFMD...laysia. Totally the disease has killed about eight...he boy. The child hailing from the town of Kapit...
...ersity of Cincinnati (UC) researchers revealed tha...ual characteristics have higher risk for depressiv...f data through surveys which said that the risk fo...eater among respondents who reported negative reli...
...e Minister Manmohan Singh set up a task force to f...of doctors, nurses and lab technicians. The recrui...an opportunity to the unemployed. The move is bas...port submitted by National Commission on Macroecon...
Other Medicine News:
(Date:8/27/2008)...prednisone arm demonstrated a, significant surviv...se -, CAMBRIDGE, Mass., Aug. 27 /- M...nced the publication of results from the 682,patie...eek,s edition of the,New England Journal of Medici...fit and a 30 percent complete remission (CR) rate ...
(Date:8/27/2008)...al, expected by mid-2009 - - Data from second Pha...CKVILLE, Md., Aug. 27 /- Hu...nnounced it has completed enrollment,and initial d... 3,randomized clinical trials of LymphoStat-B(R) (...erythematosus (SLE). Belimumab is being developed ...
(Date:8/26/2008)...mafore Pharmaceuticals Inc.,presented data at the ...es,in Cancer in Washington, D.C., announcing the d... that demonstrate significant anticancer,activity ...molecular scaffold has been developed using,comput...3 kinase inhibitors,as well as isoform-selective s...
(Date:8/26/2008)...FirstCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today a...,from the CUSTOM II trial was published in the mos...ntervention. The lead author of the article was,Dr...nter Utrecht, Utrecht,The Netherlands on behalf o...es across Europe., The one-year CUSTOM II trial, ...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Older Americans are more socially engaged than many people may think 16988 1Older Americans are more socially engaged than many people may think 16988 2Older Americans are more socially engaged than many people may think 16988 3Is there anybody out there 3F 2916 1Is there anybody out there 3F 2916 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 155 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 255 Year Old Grandmother to Document Journey of Running Seven Marathons on Seven Continents on Run7on7 com 16984 3MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 1MEDEX Global Group Hires Industry Veteran Mike Roban as Vice President of Sales 16980 2
...of Peregrine,s,Unique Selective Anti-VEGF Antibodi...l Cancer Models, TUSTIN, Calif., April 20, 2007 /P... Inc. , a clinical stage,biopharmaceutical company... treatment of cancer and hepatitis C virus infecti... presented at the recent,Centennial Annual Meeting...
...Rx Corporation,(NASDAQ:CYTR) today announced that ...clusively licensed to its majority-owned,subsidiar...,published in the April 2007 issue of peer-reviewe...hnology was developed by RXi,Co-founder, Scientifi...setts Medical School (UMMS) Professor of Biochemis...
Other Medicine Technology:Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: